<DOC>
	<DOCNO>NCT01570777</DOCNO>
	<brief_summary>The DENER-HTN study , multicenter , prospective , open , randomize , control study effectiveness cost renal denervation addition standardize medical treatment compare medical treatment alone subject resistant hypertension . Bilateral renal denervation perform use Symplicity Catheter - percutaneous system delivers radiofrequency ( RF ) energy luminal surface renal artery .</brief_summary>
	<brief_title>Renal Denervation Hypertension</brief_title>
	<detailed_description>The DENER-HTN study , multicenter , prospective , open , randomize , control study efficacy cost-effectiveness renal denervation plus standardized optimal antihypertensive treatment compare standardized optimal antihypertensive treatment alone patient proven resistant hypertension . Patients essential resistant hypertension first enter 4-week run-in period receive standardize triple combination therapy ( diuretic+ ACE inhibitor+ CCB maximal dose ) . After 4 week standardize triple therapy patient randomize renal denervation + optimal antihypertensive treatment compare standardized optimal antihypertensive treatment daytime ambulatory BP remain ≥ 135 and/or 85 mmHg . Bilateral renal denervation perform use Symplicity Catheter ( Medtronic ® ) - percutaneous system delivers radiofrequency ( RF ) energy luminal surface renal artery . Study amendment : Extended follow-up 48 month randomize patient .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Coronary Vasospasm</mesh_term>
	<criteria>Individual 18 less 75 year old time randomization Essential hypertension diagnose complete workup within past 2 year Office blood pressure ≥140 and/or 90 mmHg despite stable medication regimen include full tolerate dos 3 antihypertensive medication different class , include diuretic 2 functional kidney size ≥ 90 mm ; eGFR ≥ 40 mL/min/1.73m² ( MDRD formula ) Suitable renal anatomy compatible endovascular denervation procedure Signed Informed consent Confirmed resistant hypertension define diurnal ambulatory blood pressure measurement ≥ 135 and/or 85 mmHg 4 week standardize triple antihypertensive treatment Patients estimate glomerular filtration rate ( eGFR ) less 40 mL/min/1.73 m2 Patients secondary hypertension Kaliemia ≥ 6mmol/L Patient single function kidney Patient contrast medium allergy Patient implantable device incompatible radiofrequency energy delivery Patient contraindication antihypertensive standardized medication regimen Patient transient fix cerebral ischemia within 3 month inclusion Patient myocardial infarction , unstable angina pectoris , coronary bypass percutaneous angioplasty within 3 month inclusion Patient type 1 diabetes mellitus Patient malignancy within 5 past year Patient atrial fibrillation and/or brachial circumference ≥ 42cm</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Resistant hypertension</keyword>
	<keyword>Renal denervation</keyword>
	<keyword>Standardized medication regimen</keyword>
	<keyword>Endovascular</keyword>
	<keyword>Primary hypertension</keyword>
	<keyword>Cardiovascular disease</keyword>
	<keyword>Vascular disease</keyword>
</DOC>